Tax
Foreign Tax (Current)
Vertex Pharmaceuticals Foreign Tax (Current) remained flat by 0.0% to $121.45M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 56.8%, from $77.45M to $121.45M. Over 2 years (FY 2023 to FY 2025), Foreign Tax (Current) shows an upward trend with a 17.8% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementIncome Statement
SectionTax
CategoryEfficiency
SignalLower is better
VolatilityModerate
First reportedQ1 2013
Last reportedQ4 2025
How to read this metric
Changes reflect the tax impact of global revenue distribution and international tax compliance.
Detailed definition
The portion of the total income tax provision that is currently payable to foreign governments. This captures the immedi...
Peer comparison
Standard tax disclosure for multinational corporations.
Metric ID:
msft_current_foreign_tax_expenseHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $350.10M | $309.80M | $485.80M |
| YoY Change | — | -11.5% | +56.8% |
Range$309.80M – $485.80M
CAGR+17.8%
Avg YoY Growth+22.6%
Median YoY Growth+22.6%
Foreign Tax (Current) at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's foreign tax (current)?
- Vertex Pharmaceuticals (VRTX) reported foreign tax (current) of $121.45M in Q4 2025.
- How has Vertex Pharmaceuticals's foreign tax (current) changed year-over-year?
- Vertex Pharmaceuticals's foreign tax (current) increased by 56.8% year-over-year, from $77.45M to $121.45M.
- What is the long-term trend for Vertex Pharmaceuticals's foreign tax (current)?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's foreign tax (current) has grown at a 17.8% compound annual growth rate (CAGR), from $350.10M to $485.80M.
- What does foreign tax (current) mean?
- The amount of income tax currently owed to foreign governments for the period.